Skip to main content
$23.12 -0.24 (-1.03%) At close · Jul 23
Market Cap
$1.69B
Shares
73.02M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$105.97M +38.9%
FY2025 Revenue FY2020–FY2025
Net Income
-$81.13M +33.9%
FY2025 Net Income FY2020–FY2025
Operating Margin
-87.34% +92.4pp
FY2025 Operating Margin FY2020–FY2025
Diluted EPS
-$1.08 +33.3%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$33.01M +70%
FY2025 Operating Cash Flow FY2020–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
$81.26M $105.97M $76.3M $76.01M $412.48M $26.68M $38.95M
$135.72M $137M $134.62M $143.62M $208.6M $199.75M $171.2M
$59.6M $61.51M $61.51M $70.45M $73.36M $42.56M $55.22M
$4.06M $4.5M $2.7M $1.02M $2.79M $4.16M
$0
$195.32M $198.51M $213.41M $214.07M $281.95M $242.31M $226.42M
-$114.05M -$92.55M -$137.11M -$138.05M $130.53M -$215.63M -$187.47M
-87.34% -179.69% -181.62% 31.64% -808.22% -481.29%
-$488K -$559K $558K -$894K $1.11M $1.31M $1.65M
-$103.97M -$79.75M -$116.61M -$119.24M $135.23M -$212.36M -$180.12M
-$1.31M $1.38M $6.08M -$568K $10.89M -$516K $429K
-$102.66M -$81.13M -$122.7M -$118.67M $124.34M -$211.84M -$180.55M
-76.56% -160.8% -156.13% 30.14% -794.01% -463.54%
-$102.82M -$80.26M -$123.04M -$118.62M $124.34M -$211.84M -$180.55M
USD/shares -$1.08 -$1.62 -$1.72 $1.91 -$4.11 -$3.58
USD/shares -$1.08 -$1.62 -$1.72 $1.90 -$4.61 -$3.58
shares 75.4M 75.85M 68.86M 65.19M 51.55M 50.38M
shares 75.41M 75.88M 68.86M 65.25M 52.13M 50.38M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $71.75M in buybacks.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.58×
EV/EBIT
Biotechnology median 26.67×
P/E (TTM)
Biotechnology median 7.06×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022
Reportable Segment $105,965,000 $76,304,000 $76,012,000 $412,482,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Research Support Payments and Other Service $0 $168,000 $2,864,000 $1,773,000 $5,680,000 $7,951,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022
Reportable Segment -$56,790,000 -$95,225,000 -$119,157,000 $141,778,000

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023 FY2022
Reportable Segment -53.6% -124.8% -156.8% 34.4%
Key facts CIK 1937653 CUSIP 98985Y108 13F (30d) 23 filings 23 filers Visit website Investor relations